ENLIVEN THERAPEUTICS Directors Execute Massive Plan‑Based Sell‑Off Amid Social‑Media Surge and 52‑Week High

Insider Selling Amid a Resurgent Rally

ENLIVEN THERAPEUTICS (ENLV) is currently experiencing a notable wave of insider activity, most prominently a large block sale by director Lori Anne Kunkel on June 5. The 10‑b‑5‑1 plan, approved on March 6, allowed Kunkel to offload 7,779 shares at an average price of $34.28, followed by a second sale of 1,867 shares at $35.36 and a third of 354 shares at $35.82. These sales reduce her holdings from 54,105 to 51,884 shares, leaving her with 51,884 shares at a price only marginally above the current market price of $33.63.

What Does the Sell‑Off Mean for Investors?

While the price differential is modest, the timing of the sales—coincident with a 1.72% weekly gain and a 105 % buzz spike—suggests that insiders may be taking profits ahead of a potential market correction. Kunkel’s trades were executed under a pre‑approved plan, indicating she was not responding to inside information but rather following a systematic strategy. Nonetheless, the cumulative volume of insider sales, combined with the recent 20,000‑share sale by the board, could signal a shift in confidence among senior leadership. For long‑term holders, it’s a reminder to monitor whether this pattern continues or if it is an isolated event triggered by the recent earnings beat that pushed the stock to a 52‑week high of $48.53.

Kunkel’s Transaction Profile

Kunkel’s trading history paints a picture of a disciplined, plan‑based trader. In February, she exercised a 17,126‑share stock‑option purchase at $0.00 (i.e., at the exercise price) and subsequently sold the same number of shares in December 2025 for $1.12 each. Her most recent purchases (15,958 shares in December 2025 for $0.00) and sales (15,958 shares in December 2025 at $1.12) show a consistent pattern of buying low and selling high under the same 10‑b‑5‑1 framework. Over the past year, her net exposure has fluctuated but generally stayed below 60,000 shares, indicating a conservative approach to liquidity and risk.

Broader Insider Activity

Beyond Kunkel, ENLV’s other executives—chief medical officer Helen Collins and chief financial officer Benjamin Hohl—have been buying and selling large blocks in a similar fashion. Collins’ 30,000‑share purchase in March 2026 was offset by a series of 5,000‑share sales, while Hohl’s 25,000‑share purchase in December 2025 was later sold for $0.00. The pattern suggests that the leadership team is employing a systematic plan to manage their positions, rather than reacting to short‑term news.

Investor Takeaway

For investors, the key signals are: (1) insiders are executing plan‑based trades that align with a disciplined approach to liquidity, (2) recent sales coincide with a peak in social‑media buzz and a modest price gain, and (3) the company’s fundamentals—an 84 % year‑to‑date return and a negative P/E of –20.68—still indicate significant upside potential, albeit tempered by valuation concerns. Watch for the next 10‑b‑5‑1 filing and the board’s announced 20,000‑share sale, as these events will likely provide the most telling gauge of management confidence in ENLV’s long‑term prospects.